BDX Stock Forecast & Price Target

Becton Dickinson reported a strong performance in FQ3'25, with total sales of $888 million, marking a year-over-year increase of 5.3%, driven by robust growth in its Infusion Systems and Dispensing Solutions segments. The company has maintained consistent annual growth of over 6% since implementing its BD 2025 strategy within its MedTech business, alongside improving margins, which indicates strong operational effectiveness. Additionally, the MDS segment achieved fiscal year 2024 sales of $4.43 billion, reflecting a 3.2% increase year-over-year when adjusted for foreign exchange, underscoring the company's solid market position and revenue generation capabilities.

Becton Dickinson has maintained its organic revenue growth outlook at 3.0-3.5% year-over-year, a reduction from the previous guidance of 4.0-4.5%, indicating a downward trend in expected revenue growth. In the third fiscal quarter of 2025, the company reported sales of $1.25 billion, reflecting a 1.1% year-over-year decline, with notable weakness in its Biosciences and Diagnostic Solutions segments contributing to this downturn. Additionally, the firm faces challenges from volume-based procurement pressures in China and reduced demand due to government cuts in research funding, further complicating growth prospects.